A crackdown by regulators on deals between drugmakers that unfairly delay the launch of cheap generic medicines appears to be working, with data on Monday showing firms in Europe are avoiding settlements involving pay-offs. Generic drug firms regularly challenge the validity of branded drug patents - especially when patents are nearing the end of their life - and some companies owning the original brands have been paying rivals not to market generic versions of them. The practice has brought criticism from around the world because it inflates consumers’ bills and pushes up public healthcare costs.
Help employers find you! Check out all the jobs and post your resume.
